News
Most Oncologic Drugs Advisory Committee members took issue with the lack of dosing optimization and the lack of US patient ...
In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...
Recent developments in the health sector highlight diverse changes from drug pricing initiatives by Bristol Myers and Pfizer ...
GSK has been enjoying regulatory momentum in recent months as it works to bring its antibody-drug conjugate (ADC) Blenrep ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback